Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals Inc Cl A (NQ: RXRX )

9.510 -0.270 (-2.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals Inc Cl A

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In
The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
What's the Difference Between Biotech Stocks and TechBio Stocks?
A few enterprising businesses are marketing themselves differently. 
Via The Motley Fool
Recursion Pharm Stock Sees Relative Strength Rating Rise To 84
On Tuesday, Recursion Pharm stock had its Relative Strength (RS) Rating upgraded to 84, up from 78 a day earlier. 
Via Investor's Business Daily
Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Demystifying Recursion Pharmaceuticals: Insights From 4 Analyst Reviews
Via Benzinga
(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest
Via Benzinga
Where Will Recursion Pharmaceuticals Be in 5 Years?
A lot is riding on whether its platform is valuable, or vaporware. 
Via The Motley Fool
The Next Drug You Take May be Designed By A.I.
Three stocks could give investors a better way to tap into A.I.'s future potential inside drug development, an industry that is set to grow at 29.6% until 2030 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor Optimism
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) made waves Monday afternoon not only with the announcement of its groundbreaking BioHive-2 supercomputer but also with a notable surge in its stock... 
Via Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. 
From Recursion Pharmaceuticals
Via GlobeNewswire
Cathie Wood Is Buying This Under-the-Radar AI Stock
This company has massive upside potential, but that's not the whole story. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
RXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
RXRX stock results show that Recursion Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Nvidia-Backed Recursion Pharmaceuticals Stock Is Up On Q1 Earnings: Everything You Need To Know
Recursion reported first-quarter revenue of $13.491 million, which beat analyst estimates of $12.65 million, according to Benzinga Pro. The company reported a quarterly loss of 39 cents per share,... 
Via Benzinga
Nvidia Favorite SoundHound AI Delivers Beat-And-Raise Report
SoundHound AI, which counts Nvidia as an investor, beat estimates for the first quarter and with its sales guidance. SOUN stock rose. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
Company to host public L(earnings) Call on May 9 at 5:00 pm ET 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program
The grant designates Altitude Lab as a top acceleration program for biotechnology startups 
From Recursion Pharmaceuticals
Via GlobeNewswire
Nvidia Owns a 3.4% Stake in This Innovative Artificial Intelligence (AI) Stock Cathie Wood Loves
The $50 million purchase could turn into Nvidia's biggest investment. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
The Top 3 Biotech Stocks to Buy in April 2024
Learn about the top three biotech stocks to take advantage of these companies' promising futures and pharmaceutical advances. 
Via InvestorPlace
3 Millionaire-Maker Biotech Stocks
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential. 
Via The Motley Fool
Jim Cramer Says This Energy Stock Is 'Terrific,' Calls Casey's General Stores A 'Winner'
Cramer recommends selling PBR, buying EPD, LNG, RXRX, and CASY. Criticisms of AVGO's licensing changes dismissed. PBR and CASY stocks rise. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
Via Talk Markets
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.